Growth without growth hormone receptor:: Estradiol is a major growth hormone-independent regulator of hepatic IGF-I synthesis

被引:56
|
作者
Venken, K
Schuit, F
Van Lommel, L
Tsukamoto, K
Kopchick, JJ
Coschigano, K
Ohlsson, C
Movérare, S
Boonen, S
Bouillon, R
Vanderschueren, D
机构
[1] Katholieke Univ Leuven, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium
[2] Katholieke Univ Leuven, Div Biochem, Gene Express Unit, B-3000 Louvain, Belgium
[3] Ohio Univ, Edison Biotechnol Inst, Athens, OH 45701 USA
[4] Ohio Univ, Dept Biomed Sci, Athens, OH 45701 USA
[5] Univ Gothenburg, Sahlgrenska Acad, Dept Internal Med, Ctr Bone Res, Gothenburg, Sweden
[6] Katholieke Univ Leuven, Univ Louvain, Ctr Metab Bone Dis, Louvain, Belgium
[7] Katholieke Univ Leuven, Div Geriatr Med, Louvain, Belgium
关键词
growth hormone receptor knockout mouse; bone; estrogens; IGF-I; liver gene expression;
D O I
10.1359/JBMR.050811
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The role of estrogens in the regulation of pubertal growth independently of GH and its receptor was studied in male mice with disrupted GHRKO. E-2 rescued skeletal growth rates in GHRKO associated with an increase in hepatic and serum IGF-I. These data show that E-2 rescues pubertal growth during GH resistance through a novel mechanism of GHR-independent stimulation of hepatic IGF-I production. Introduction: Growth hormone (GH) and estrogen play a pivotal role in pubertal growth and bone mineral acquisition. Estrogens can affect GH secretion and thereby provide a GH-dependent mechanism for their effects on skeletal growth. It is presently unclear if or to what extent estrogens are able to regulate pubertal growth and bone mineral accrual independently of GH and its receptor. Materials and Methods: Estradiol (E-2; 0.03 mu g/day by subcutaneous silastic implants) was administered to orchidectomized (ORX) male mice with disrupted GHR (GHRKO) and corresponding WTs during late puberty (6-10 weeks). Longitudinal and radial bone growth, IGF-I in serum and its expression in liver, muscle, and bone, and liver gene expression were studied by histomorphometry, RIA, RT-PCR, microarrays, and Western blotting, respectively. Results: E-2 stimulated not only longitudinal (femur length and growth plate thickness) and radial growth (cortical thickness and periosteal perimeter), but also rescued longitudinal and periosteal growth rates in ORX GHRKO, whereas no significant changes occurred in WT. E-2 thereby upregulated serum IGF-I and liver IGF-I synthesis (+21% and +52%, respectively) in ORX GHRKO, whereas IGF-I synthesis in femur or muscle was unaffected. Study of the underlying mechanism of the stimulation of hepatic IGF-I expression showed that E-2 restored downregulated receptor signaling systems, such as the estrogen receptor alpha and the prolactin receptor. E-2 thereby recovered the Janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathway as evidenced by a significantly increased activation of the transcription factor STAT5 in ORX GHRKO. Conclusions: Our data show a stimulation of skeletal growth through upregulation of hepatic IGF-I by a hormone other than GH. E-2 rescues pubertal skeletal growth during GH resistance through a novel mechanism of GHR-independent stimulation of IGF-I synthesis in the liver.
引用
收藏
页码:2138 / 2149
页数:12
相关论文
共 50 条
  • [21] Regulation of insulin-like growth factor I (IGF-I) and receptors for IGF-I and growth hormone in the heart
    Isgaard, J
    Friberg, P
    ENDOCRINOLOGY AND METABOLISM, 1997, 4 : 15 - 19
  • [22] Growth promoting effects of growth hormone and IGF-I are additive in experimental uremia
    Kovacs, GT
    Oh, J
    Kovacs, J
    Tonshoff, B
    Hunziker, EB
    Zapf, J
    Mehls, O
    KIDNEY INTERNATIONAL, 1996, 49 (05) : 1413 - 1421
  • [23] Effect of circulating growth hormone on muscle IGF-I protein concentration in female mice with growth hormone receptor gene disruption
    Kraemer, William J.
    Vingren, Jakob L.
    Schuenke, Mark D.
    Kopchick, John J.
    Volek, Jeff S.
    Fragala, Maren S.
    Hakkinen, Keijo
    Jen-Ho
    Thomas, Gwendolyn A.
    Staron, Robert S.
    GROWTH HORMONE & IGF RESEARCH, 2009, 19 (03) : 242 - 244
  • [24] SHOX Gene Variants: Growth Hormone/IGF-I Status and Response to Growth Hormone Treatment.
    Shapiro, S.
    Klein, M. L.
    Regelmann, M. O.
    Fen, Y.
    Wallach, E. J.
    Hyman, S. J.
    Godbold, J. H.
    Rapaport, R.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [25] EFFECTS OF GROWTH-HORMONE AND IGF-I ON GLOMERULAR ULTRAFILTRATION IN GROWTH HORMONE-DEFICIENT RATS
    HIRSCHBERG, R
    REGULATORY PEPTIDES, 1993, 48 (1-2) : 241 - 250
  • [26] Growth retardation due to an IGF-I receptor gene deletion can be effectively treated with growth hormone
    Boot, Annemieke
    Walenkamp, Marie Jose
    Schrama, Sabine de Muinck Keizer
    Mos de, M.
    Kalf, M. E.
    Losekoot, Monique
    Duyvenvoorde van, H. A.
    Kant, S. G.
    Den Dunnen, J. T.
    Karperien, Marcel
    Wit, Jan Maarten
    HORMONE RESEARCH, 2006, 65 : 72 - 72
  • [27] Growth hormone receptor abundance in tibial growth plates of uremic rats: GH/IGF-I treatment
    Edmondson, SR
    Baker, NL
    Oh, J
    Kovacs, G
    Werther, GA
    Mehls, O
    KIDNEY INTERNATIONAL, 2000, 58 (01) : 62 - 70
  • [28] PROLACTIN AND SOMATOMEDIN STUDIES IN SYNDROME OF GROWTH HORMONE-INDEPENDENT GROWTH
    GLUCKMAN, PD
    HOLDAWAY, IM
    CLINICAL ENDOCRINOLOGY, 1976, 5 (05) : 545 - 549
  • [29] GROWTH-HORMONE INDUCTION AND SOMATOSTATIN SUPPRESSION OF HEPATIC PROTOONCOGENES AND IGF-I IN THE RAT
    PENMAN, J
    LIU, S
    BELCHETZ, P
    GOLDSPINK, DF
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1995, 23 (02) : S328 - S328
  • [30] Growth hormone, IGF-I, and the elderlyClues to potential therapeutic interventions
    Clifford J. Rosen
    Endocrine, 1997, 7 : 39 - 40